Testing sterility when the product cannot wait fourteen days: why rapid sterility testing exists for short shelf life products and what a rapid method has to demonstrate against the compendial one before it can replace it, what laboratory sterilizers and the cycles they run contribute upstream, where genetic stability testing and raw material testing sit in the same release package, what protein purity analysis and a protein analyzer report about the product rather than about its sterility, and what a release decision needs on file before material can be used

Building the release package

1. Validate a rapid method against the compendial one. Equivalence has to be demonstrated for the organisms and the product in question, including a method suitability test showing the product does not inhibit growth. Adopting a rapid method without that is not a shortcut, it is an unvalidated result.
2. Run method suitability before any sample. Products with antimicrobial properties inhibit the test itself. Demonstrating that a known low inoculum still grows in the presence of the product is what makes a negative result meaningful.
3. Control the upstream sterilisation. Sterility at release depends on validated sterilisation cycles and aseptic handling upstream. A test is a check on a process, not a substitute for one.
4. Include stability and identity in the package. Genetic stability for a cell or vector product, identity, purity and potency alongside sterility. A release package with sterility alone answers one question out of several.
5. Test incoming materials to a written plan. Raw material testing on receipt, to a defined plan with acceptance criteria, prevents a failure that only becomes visible at release when the batch is already made.
6. Decide what happens on a positive result. Investigation route, retest policy where permitted, and the disposition of the batch. Deciding this in advance is what keeps a positive from becoming an argument.

Speed is bought with validation

Rapid methods are attractive precisely where the product is short lived, and that is also where a false negative is least recoverable. The validation is therefore more important, not less.

Plan it as a project with its own timeline. Programmes that adopt a rapid method late discover the validation is on the critical path.

A test checks a process

Sterility testing samples a small fraction of a batch and cannot demonstrate sterility of the whole. Confidence comes from validated sterilisation, aseptic process simulation and environmental monitoring, with the test as a final check.

Where the process control is weak, more testing does not compensate. That is a well established point and it is worth stating internally before a release argument begins.

Common questions

Can a rapid method replace the compendial test?

With a validation demonstrating equivalence or superiority for your product and the relevant organisms, and with the regulator informed as required. Without it the rapid result is supporting information rather than a release test.

Why does method suitability come first?

Because a product with antimicrobial activity can suppress growth in the test, turning a contaminated batch into a passing result. Demonstrating recovery of a low inoculum in the presence of the product is what excludes that.

What else belongs in a release package?

Identity, purity, potency, endotoxin and, for cell and vector products, stability and adventitious agent testing. Sterility is one line in a panel rather than the panel.

Browse by service class

• Compare Gene synthesis on advertised prices